BioSpace News Archive

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on Monday, September 14, 2020, at 4:30 p.m. ET.

In PNEU-AGE (V114-019), V114 Demonstrated Non-inferiority to the Currently Available 13-valent Pneumococcal Conjugate Vaccine for Shared Serotypes and Met Study-Defined Superiority Criteria for Unique Serotypes 22F and 33F and Shared Serotype 3

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that the company will present at two investor conferences in September.

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the following virtual investor conferences in September

Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma.

Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group

Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) in late 2020 or early 2021.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that RedHill’s Chief Executive Officer, Dror Ben-Asher, will present at the Morgan Stanley Annual Global Healthcare Conference, on Thursday, September 17, 2020.

Amarin Corporation plc announced that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 from 11:20 - 11:50 a.m. Eastern Time.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference 2020, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.